T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis.

Recombinant T-cell receptors with antibody-like specificity are successfully used to direct CTLs toward a MHC-independent immune response against target cells. Here we monitored the specific activation of receptor grafted CTLs in the context of CD28 costimulation. Peripheral blood T cells were retrovirally engrafted with recombinant anti-CD30 and anti-carcinoembryonic antigen receptors, respectively, that harbor either the Fc epsilonRI-gamma or the CD3-zeta intracellular signaling domain. Cross-linking of recombinant receptors by solid-phase bound ligand, i.e., CD30 and a carcinoembryonic antigen receptor-specific anti-idiotypic antibody, respectively, induces IFN-gamma secretion that is further enhanced by CD28 costimulation of grafted T cells. Induction of interleukin (IL)-2 secretion, in contrast, requires CD28 costimulation in addition to receptor cross-linking, irrespective of T-cell preactivation by anti-CD3 monoclonal antibody plus IL-2 or by anti-CD3 monoclonal antibody plus anti-CD28 monoclonal antibody. Accordingly, induction of IL-2 secretion upon receptor cross-linking by membrane-bound antigen requires CD28/B7 costimulation whereas IFN-gamma secretion and cell proliferation does not. The efficiency of cytolysis by receptor-grafted CTLs does not depend on and is not affected by CD28 costimulation. The data demonstrate that CTL proliferation, cytokine secretion, and cytolysis upon receptor cross-linking are differentially modulated by CD28 costimulation and that cytolysis does not require B7 expression on target cells.

[1]  V. Diehl,et al.  An entirely humanized CD3 ζ‐chain signaling receptor that directs peripheral blood t cells to specific lysis of carcinoembryonic antigen–positive tumor cells , 2000, International journal of cancer.

[2]  V. Diehl,et al.  T cell activation by recombinant FcεRI γ-chain immune receptors: an extracellular spacer domain impairs antigen-dependent T cell activation but not antigen recognition , 2000, Gene Therapy.

[3]  J. Frelinger,et al.  Naive CD8+ T Cells Do Not Require Costimulation for Proliferation and Differentiation into Cytotoxic Effector Cells1 , 2000, The Journal of Immunology.

[4]  M. Krummel,et al.  Differential coupling of second signals for cytotoxicity and proliferation in CD8+ T cell effectors: amplification of the lytic potential by B7. , 1999, Journal of immunology.

[5]  Seliger,et al.  Gene Transfer of the Co‐Stimulatory Molecules B7‐1 and B7‐2 Enhances the Immunogenicity of Human Renal Cell Carcinoma to a Different Extent , 1999, Scandinavian journal of immunology.

[6]  M. Mescher,et al.  ICAM‐1 and B7‐1 provide similar but distinct costimulation for CD8+ T cells, while CD4+ T cells are poorly costimulated by ICAM‐1 , 1999, European journal of immunology.

[7]  M. Weijtens,et al.  A retroviral vector system ‘STITCH’ in combination with an optimized single chain antibody chimeric receptor gene structure allows efficient gene transduction and expression in human T lymphocytes , 1998, Gene Therapy.

[8]  B. V. van Krimpen,et al.  Chimeric scFv/γ receptor‐mediated T‐cell lysis of tumor cells is coregulated by adhesion and accessory molecules , 1998, International journal of cancer.

[9]  J. Langhorne,et al.  A flow cytometric method to assess antigen-specific proliferative responses of different subpopulations of fresh and cryopreserved human peripheral blood mononuclear cells. , 1998, Journal of immunological methods.

[10]  V. Diehl,et al.  A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA , 1998, Gene Therapy.

[11]  V. Diehl,et al.  An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30. , 1998, Cancer research.

[12]  T. Mak,et al.  Duration of TCR stimulation determines costimulatory requirement of T cells. , 1996, Immunity.

[13]  J. Sprent,et al.  Influence of antigen dose and costimulation on the primary response of CD8+ T cells in vitro , 1996, The Journal of experimental medicine.

[14]  S. Rosenberg,et al.  In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. , 1995, Cancer research.

[15]  M. Croft,et al.  Costimulatory requirements of naive CD4+ T cells. ICAM-1 or B7-1 can costimulate naive CD4 T cell activation but both are required for optimum response. , 1995, Journal of immunology.

[16]  U. Şahin,et al.  The role of lymphocyte subsets and adhesion molecules in T cell‐dependent cytotoxicity mediated by CD3 and CD28 bispecific monoclonal antibodies , 1995, European journal of immunology.

[17]  J. Bluestone,et al.  The B7 and CD28 receptor families. , 1994, Immunology today.

[18]  B. Groner,et al.  Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[19]  V. Diehl,et al.  CD30‐specific AB1‐AB2‐AB3 internal image antibody network: Potential use as anti‐idiotype vaccine against Hodgkin's lymphoma , 1993, International journal of cancer.

[20]  Z. Eshhar,et al.  Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[21]  J. Kirkwood,et al.  Improved short- and long-term XTT-based colorimetric cellular cytotoxicity assay for melanoma and other tumor cells. , 1992, Journal of immunological methods.

[22]  V. Diehl,et al.  Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumors in mice. , 1990, Cancer research.

[23]  U. Reinhold,et al.  Can combined T-cell- and antibody-based immunotherapy outsmart tumor cells? , 1998, Immunology today.

[24]  P. Morel,et al.  Crossregulation between Th1 and Th2 cells. , 1998, Critical reviews in immunology.

[25]  V. Kuchroo,et al.  CD28/B7 costimulation: a review. , 1998, Critical reviews in immunology.

[26]  W. Dippold,et al.  Humanized anti-carcinoembryonic antigen antibody: strategies to enhance human tumor cell killing. , 1993, The Year in immunology.